Iron Deficiency Anemia at Time of Vaccination Predicts Decreased Vaccine Response and Iron Supplementation at Time of Vaccination Increases Humoral Vaccine Response: A Birth Cohort Study and a Randomized Trial Follow-Up Study in Kenyan Infants.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsStoffel, Nicole U
Uyoga, Mary A
Mutuku, Francis M
Frost, Joe N
van der Klis, Fiona R M
Malhotra, Indu J
LaBeaud, A Desiráe
King, Charles H
Zimmermann, Michael B
MetadataShow full item record
TitleIron Deficiency Anemia at Time of Vaccination Predicts Decreased Vaccine Response and Iron Supplementation at Time of Vaccination Increases Humoral Vaccine Response: A Birth Cohort Study and a Randomized Trial Follow-Up Study in Kenyan Infants.
Published inFront Immunol 2020; 11:1313
- Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
- Authors: Wood N, Nolan T, Marshall H, Richmond P, Gibbs E, Perrett K, McIntyre P
- Issue date: 2018 Nov 1
- The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses.
- Authors: Zimmermann P, Perrett KP, Messina NL, Donath S, Ritz N, van der Klis FRM, Curtis N
- Issue date: 2019 Aug
- Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age.
- Authors: Wood N, McIntyre P, Marshall H, Roberton D
- Issue date: 2010 Mar
- Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.
- Authors: Rouers EDM, Bruijning-Verhagen PCJ, van Gageldonk PGM, van Dongen JAP, Sanders EAM, Berbers GAM
- Issue date: 2020 Sep 15
- Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
- Authors: Barug D, Pronk I, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, Berbers GAM, Sanders EAM, Rots NY
- Issue date: 2019 Apr
Showing items related by title, author, creator and subject.
Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females.van der Weele, Pascal; Breeuwsma, Martijn; Donken, Robine; van Logchem, Elske; van Marm-Wattimena, Naomi; de Melker, Hester; Meijer, Chris J L M; King, Audrey J (2019-01-01)HPV vaccination with the bivalent vaccine is efficacious against HPV16 and 18 infections and cross-protection against non-vaccine HPV types has been demonstrated. Here, we assessed (cross-) protective effects of the bivalent HPV16/18 vaccine on incident and persistent infections and viral load (VL) of fifteen HPV types in an observational cohort study monitoring HPV vaccine effects. Vaginal samples were obtained annually. Type-specific VL assays were developed for HPV6,11,31 33,35,39,45,51,52,56,58,59 and 66 and used in addition to existing HPV16 and 18 assays. Rate differences of incident clearing and persistent infections were correlated with differences in VL and vaccination status. HPV16/18 vaccination resulted in significantly lower incidence of HPV16/18 infections and significantly lower VL in breakthrough HPV16 (p<0.01) and 18 infections (p<0.01). The effects of vaccination on non-vaccine type VL were ambiguous. Incidence and/or persistence rates of HPV31, 33, 35 and 45 were reduced in the vaccinated group. However, no significant type specific VL effects were found against HPV31, 33, 45, 52 in the vaccinated group. For HPV 6, 59 and 66 no significant reductions in numbers of incident and persistent infections were found, however borderline) VL reductions following vaccination were observed for HPV6 (p = 0.01), 59 (p = 0.10) and 66 (p = 0.03), suggesting a minor effect of the vaccine on the VL level of these HPV types. Overall, vaccination resulted in infections with slightly lower VL, irrespective of HPV type. In conclusion, vaccination with the bivalent HPV16/18 vaccine results in significantly reduced numbers of HPV16 and 18 incidence rates and reduced VL in breakthrough infections. Significant reductions in incident and/or persistent HPV31, 33, 35 and 45 infections were found, but no significant effect was observed on the VL for infections with these types. For the other non-vaccine HPV types no reduction in incident and/or persistent infections were found, but overall the VL tended to be somewhat lower in vaccinated women.
Immune Responses After 2 Versus 3 Doses of HPV Vaccination up to 4½ Years After Vaccination: An Observational Study Among Dutch Routinely Vaccinated Girls.Donken, Robine; Schurink-Van't Klooster, Tessa M; Schepp, Rutger M; van der Klis, Fiona R M; Knol, Mirjam J; Meijer, Chris J L M; de Melker, Hester E (2017-02-01)In 2014 the Netherlands switched from 3 to 2 doses for routine vaccination with the prophylactic bivalent human papillomavirus (HPV) vaccine. The current study explored whether antibody responses are noninferior after 2 versus 3 doses in girls.
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium.Kho, Marcia M L; Reinders, Marlies E J; Baan, Carla C; van Baarle, Debbie; Bemelman, Frederike J; Diavatopoulos, Dimitri A; Gansevoort, Ron T; van der Klis, Fiona R M; Koopmans, Marion P G; Messchendorp, A Lianne; et al. (2021-05-26)